3/30
07:20 am
cogt
We're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn Rate [Yahoo! Finance]
Medium
Report
We're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn Rate [Yahoo! Finance]
3/25
04:31 pm
cogt
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
Medium
Report
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
3/11
07:45 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
3/7
09:13 am
cogt
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference [Yahoo! Finance]
Medium
Report
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference [Yahoo! Finance]
3/7
08:17 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $17.00 price target on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $17.00 price target on the stock.
3/7
08:00 am
cogt
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
Medium
Report
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
2/27
08:08 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at Robert W. Baird from $10.00 to $8.00. They now have a "neutral" rating on the stock.
High
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at Robert W. Baird from $10.00 to $8.00. They now have a "neutral" rating on the stock.
2/27
08:00 am
cogt
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
High
Report
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
2/26
08:00 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
2/25
12:14 pm
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
2/25
09:34 am
cogt
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Low
Report
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
2/25
08:00 am
cogt
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Medium
Report
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
2/10
10:01 am
cogt
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting [Yahoo! Finance]
Low
Report
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting [Yahoo! Finance]
2/10
09:15 am
cogt
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting
Low
Report
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting
1/30
08:36 am
cogt
Cogent Biosciences to Participate in the Guggenheim Biotech Conference [Yahoo! Finance]
Low
Report
Cogent Biosciences to Participate in the Guggenheim Biotech Conference [Yahoo! Finance]
1/30
08:00 am
cogt
Cogent Biosciences to Participate in the Guggenheim Biotech Conference
Low
Report
Cogent Biosciences to Participate in the Guggenheim Biotech Conference
1/15
04:41 am
cogt
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/14
08:02 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at HC Wainwright from $17.00 to $14.00. They now have a "buy" rating on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at HC Wainwright from $17.00 to $14.00. They now have a "buy" rating on the stock.
1/13
06:17 pm
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
1/13
08:00 am
cogt
Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
Low
Report
Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
1/8
08:00 am
cogt
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
High
Report
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference